Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMA202 |
Synonyms | |
Therapy Description |
IMA202 is a TCR engineered T-cell therapy, which consists of autologous patient-derived T-cells that are modified to express T-cell receptors that recognizes patient-specific tumor associated antigens (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMA202 | IMA-202|IMA 202 | IMA202 is a TCR engineered T-cell therapy, which consists of autologous patient-derived T-cells that are modified to express T-cell receptors that recognizes patient-specific tumor associated antigens (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Completed | USA | DEU | 0 |